THE WOODLANDS, Texas,
April 27 /PRNewswire-FirstCall/ --
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical
company focused on discovering and developing breakthrough
treatments for human disease, announced today that the company will
be giving poster and oral presentations on results from its Phase 2
clinical study with LX1031 in patients with non-constipating
irritable bowel syndrome (IBS) at Digestive Disease Week (DDW) 2010
in New Orleans, Louisiana. Results
from the study, in which LX1031 produced improvements in IBS
symptoms, will be presented during the poster session on
Sunday, May 2, 2010 from 12 p.m. to 2 p.m. Central Time and the oral
presentation on Wednesday, May 5,
2010 at 9:30 a.m. CT (session
start time is 8:30 a.m. CT).
DDW is the world's largest gathering of physicians and
researchers in the fields of gastroenterology, hepatology,
endoscopy and gastrointestinal surgery. Every year it attracts
approximately 16,000 physicians, researchers and academics from
around the world.
Clinical development of LX1031 is being funded through a product
development collaboration with Symphony Capital Partners, L.P. and
its co-investors.
For more information on this program, and to access the
presentations (available after May 5,
2010), please visit www.lexpharma.com.
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering
and developing breakthrough treatments for human disease. Lexicon
currently has four drug candidates in mid-stage development for
diabetes, irritable bowel syndrome, carcinoid syndrome and
rheumatoid arthritis, all of which were discovered by Lexicon's
research team. Lexicon has used its proprietary gene knockout
technology to identify more than 100 promising drug targets.
Lexicon has focused drug discovery efforts on these
biologically-validated targets to create its extensive pipeline of
clinical and preclinical programs. For additional information about
Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements,"
including statements relating to Lexicon's clinical development
of LX1031 and the potential therapeutic and commercial potential of
LX1031. This press release also contains forward-looking
statements relating to Lexicon's growth and future operating
results, discovery and development of products, strategic alliances
and intellectual property, as well as other matters that are not
historical facts or information. All forward-looking statements are
based on management's current assumptions and expectations and
involve risks, uncertainties and other important factors,
specifically including those relating to Lexicon's ability to
successfully conduct clinical development of LX1031 and preclinical
and clinical development of its other potential drug candidates,
advance additional candidates into preclinical and clinical
development, obtain necessary regulatory approvals, achieve its
operational objectives, obtain patent protection for its
discoveries and establish strategic alliances, as well as
additional factors relating to manufacturing, intellectual property
rights, and the therapeutic or commercial value of its drug
candidates, that may cause Lexicon's actual results to be
materially different from any future results expressed or implied
by such forward-looking statements. Information identifying such
important factors is contained under "Factors Affecting
Forward-Looking Statements" and "Risk Factors" in Lexicon's annual
report on Form 10-K for the year ended December 31, 2009, as filed with the Securities
and Exchange Commission. Lexicon undertakes no obligation to update
or revise any such forward-looking statements, whether as a result
of new information, future events or otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.